Seven-Year Clinical Trial $8.5 Million Funding For Novel IBS Treatment Developed At UBIrritable bowel syndrome is a chronic, debilitating disorder affecting 25 million people in the U.S -- 14-24 percent of women and 5-19 percent of men. No reliable and satisfactory medical treatment exists for the full range of IBS symptoms, which can cause severe physical and psychological distress and deprive sufferers of their quality of life.
Successful IBS Treatment With Peppermint Oil, Antispasmodics, And Fiber According to a study published on bmj.com, doctors should recommend fiber, antispasmodics, and peppermint oil as first-line treatments for irritable bowel syndrome (IBS). Recent proof of the effectiveness of these treatments should also lead to changes in the national guidelines that specify how to manage IBS. Affecting between 5% and 20% of the population, IBS is a condition that causes abdominal pain and irregular bowel movements.
A Faster Test For The Food Protein That Triggers Celiac Disease - Analytical Chemistry JournalResearchers in Spain and the United Kingdom are reporting development of a faster test for identifying the food protein that triggers celiac disease, a difficult-to-diagnose digestive disease involving the inability to digest protein called gluten that occurs in wheat, oats, rye, and barley. The finding could help millions of people avoid diarrhea, bloating, and other symptoms that occur when they unknowingly eat foods containing gluten.
Philips' Intelligent Pill Targets Drug Development And Treatment For Digestive Tract DiseasesAt this week's opening of the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition (Atlanta, USA, November 16-20, 2008) Philips Research will announce its new intelligent pill technology "iPill", targeted at assisting drug development and enabling new therapies for debilitating and life-threatening digestive tract disorders such as Crohn's disease, colitis and colon cancer.
Newly Discovered Immune Cell May Help Those With Crohn's And ColitisThe tonsils and lymphoid tissues in the intestinal tract that help protect the body from external pathogens are the home base of a rare immune cell newly identified by researchers at Washington University School of Medicine in St. Louis. The researchers indicate that the immune cells could have a therapeutic role in inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis.
APRISO(TM) Granted FDA Marketing Approval For Maintenance Of Remission Of Ulcerative ColitisSalix Pharmaceuticals, Ltd. (NASDAQ: SLXP) today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for APRISO(TM) (mesalamine) extended-release capsules 0.375 g. APRISO is a locally-acting aminosalicylate indicated for the maintenance of remission of ulcerative colitis (UC) in adults. APRISO is the first and only mesalamine product approved by the FDA for once-a-day dosing for the maintenance of remission of ulcerative colitis.
APRISO™ Granted FDA Marketing Approval For Maintenance Of Remission Of Ulcerative ColitisSalix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for APRISO™ (mesalamine) extended-release capsules 0.375 g. APRISO is a locally-acting aminosalicylate indicated for the maintenance of remission of ulcerative colitis (UC) in adults. APRISO is the first and only mesalamine product approved by the FDA for once-a-day dosing for the maintenance of remission of ulcerative colitis.
Alvine Pharmaceuticals Reports Positive Results With ALV003 In Phase 1 Trial Of Therapy In Development For Celiac DiseaseAlvine Pharmaceuticals, Inc., today announced proof of concept in a Phase 1 Trial of ALV003, an oral protease therapy in development to detoxify gluten, intended for use by patients with celiac disease. The trial results confirmed that single doses of up to 1,800 mg of ALV003 were safe and tolerable in healthy volunteers. Doses at the 300 mg level achieved up to a 96% reduction of gluten in a meal in the stomach at 30 minutes, and were well tolerated by patients with celiac disease.
New Information Guides Available For Patients Diagnosed With Inflammatory Bowel DiseaseTo help those with inflammatory bowel disease (IBD) be better informed and involved in managing their disease, the European Foundation of Crohn's & Ulcerative Colitis Associations (EFCCA) has launched a new series of guides titled "Life and IBD". For over one million people across Europe who have it, IBD can be an overwhelming experience with new physicians, medications and terminology.
The Effectiveness Of Probiotics In IBSSeveral studies presented at the American College of Gastroenterology's 73rd Annual Scientific Meeting in Orlando highlight the safety and efficacy of probiotics in improving symptoms and normalizing bowel movement frequency in patients suffering from constipation or diarrhea related to Irritable Bowel Syndrome (IBS).
Vitamin D Deficiency Common In Patients With IBD, Chronic Liver DiseaseVitamin D replacement may be necessary to reverse deficiency-related bone loss New research presented at the 73rd Annual Scientific Meeting of the American College of Gastroenterology in Orlando found patients with inflammatory bowel disease or chronic liver disease were at increased risk of developing Vitamin D deficiencies. Two separate studies highlight the importance of regular Vitamin D checkups in the evaluation of patients with certain digestive diseases.
![](\"http://www.igotyourindex.com/igyindex.gif?DOCUMENTNAME=&DOCUMENTLINK=&GOALNAME&=DOCUMENTVALUE&=GROUPNAME\")